Kalaris Therapeutics (NASDAQ:KLRS) Trading Up 0.9% - What's Next?

Key Points

• Kalaris Therapeutics (NASDAQ:KLRS) saw its shares increase by 0.9%, with a trading range between $4.64 and $4.74, despite significantly lower trading volume compared to the average.
• Analysts have mixed views on Kalaris, with one rating it a strong buy and another assigning a hold rating, leading to an average price target of $3.00.
• The company reported a quarterly loss, with an EPS of ($0.61), falling short of the consensus estimate by $0.10.

Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) traded up 0.9% during mid-day trading on Tuesday . The stock traded as high as $4.74 and last traded at $4.68. 84,795 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 673,934 shares. The stock had previously closed at $4.64.

Analyst Ratings Changes

A number of research firms have commented on KLRS. Piper Sandler set a $3.00 price target on shares of Kalaris Therapeutics and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Wall Street Zen upgraded shares of Kalaris Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, June 17th. Finally, Raymond James Financial started coverage on shares of Kalaris Therapeutics in a report on Tuesday, September 2nd. They set a "strong-buy" rating for the company. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $3.00.

Kalaris Therapeutics Stock Performance

The business has a fifty day simple moving average of $2.99.

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.10).

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Kalaris Therapeutics stock. XTX Topco Ltd purchased a new position in Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 24,234 shares of the company's stock, valued at approximately $65,000. XTX Topco Ltd owned approximately 0.13% of Kalaris Therapeutics at the end of the most recent reporting period. Institutional investors own 66.05% of the company's stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.